This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Nuclear receptor (biology) | |
|---|---|
| Name | Nuclear receptor |
| Caption | Schematic of a nuclear receptor bound to DNA and ligand |
Nuclear receptor (biology) Nuclear receptors are a superfamily of ligand-regulated transcription factors that modulate gene expression in response to small lipophilic molecules. They integrate signals from French Academy of Sciences, Royal Society, Max Planck Society historical biochemical discoveries to control development, metabolism, and homeostasis across animals, plants, fungi, and protists. Members convey hormonal, nutritional, and xenobiotic information from cytoplasm or nucleus to chromatin, linking pathways investigated by researchers at institutions such as National Institutes of Health, European Molecular Biology Laboratory, and Howard Hughes Medical Institute.
Nuclear receptors were first characterized through studies of steroid action by investigators associated with Nobel Prize, Rockefeller University, and University of Cambridge laboratories. These proteins respond to endogenous ligands like steroids, thyroid hormones, retinoids, and bile acids, as shown in work from Columbia University, Yale University, and University of Tokyo. Nuclear receptors form a bridge between classical endocrinology discoveries at institutions like Endocrine Society conferences and modern genomics efforts at the Wellcome Trust Sanger Institute.
Nuclear receptors share a conserved modular architecture defined by studies at Cold Spring Harbor Laboratory and Pasteur Institute. The canonical domains include an N-terminal activation function (AF-1) linked to a highly conserved central DNA-binding domain (DBD) containing two zinc finger motifs characterized by coordination of cysteines and interactions defined in structures from Protein Data Bank, European Synchrotron Radiation Facility, and Max Planck Institute for Biochemistry. A hinge region connects the DBD to a C-terminal ligand-binding domain (LBD) that contains the ligand-dependent activation function (AF-2). Crystallographic and cryo-EM studies from groups at University of California, San Francisco, Massachusetts Institute of Technology, and Imperial College London revealed conformational changes in the LBD upon ligand binding that regulate cofactor recruitment involving proteins studied at Stanford University and University of Oxford.
Ligands include steroid hormones like cortisol and estrogen, thyroid hormone, retinoic acid, vitamin D, and metabolic intermediates characterized in analyses at Johns Hopkins University and Salk Institute. Binding to the LBD induces conformational rearrangements described in reports from European Molecular Biology Laboratory that reposition helix 12 to create or occlude surfaces for coactivator or corepressor interaction; these interactions involve motifs discovered at University of Pennsylvania and Duke University. Orphan nuclear receptors, identified in screens at National Cancer Institute and Cold Spring Harbor Laboratory, lack known endogenous ligands and can be regulated by post-translational modifications cataloged by researchers at Broad Institute and Ludwig Institute for Cancer Research.
Phylogenetic and functional classification divides nuclear receptors into NR0–NR6 groups as organized by international consortia including teams at European Bioinformatics Institute and National Center for Biotechnology Information. Major families include steroid hormone receptors (e.g., glucocorticoid receptor studied at Yale University), thyroid hormone receptors (pioneered at Karolinska Institute), retinoic acid receptors (elucidated at Institut Pasteur), and peroxisome proliferator-activated receptors (PPARs) characterized at University of Texas Southwestern Medical Center. Comparative genomics projects involving Broad Institute, Wellcome Trust Sanger Institute, and Max Planck Society trace diversification across metazoans and link receptor evolution to developmental gene regulatory networks investigated at Howard Hughes Medical Institute.
Nuclear receptors bind specific DNA response elements in promoters and enhancers, an activity mapped by chromatin studies from labs at Harvard Medical School, Columbia University, and Stanford University. The DBD recognizes hormone response elements composed of direct, inverted, or everted repeats; cooperative interactions with heterodimeric partners such as RXR were defined in research at University of California, San Diego and University of Edinburgh. Ligand-dependent recruitment of coactivators (e.g., p300/CBP) and corepressors (e.g., NCoR, SMRT) mediates histone modification and chromatin remodeling, processes analyzed by consortia including ENCODE and groups at Cold Spring Harbor Laboratory.
Nuclear receptors regulate development, metabolism, reproduction, circadian rhythms, and xenobiotic responses discovered in field-shaping studies at Salk Institute, University of Cambridge, and Max Planck Institute for Plant Breeding Research. Examples include glucocorticoid receptor control of stress responses elucidated at University of Toronto, estrogen receptor roles in reproductive physiology investigated at Johns Hopkins University, and PPARs in lipid metabolism probed at Mayo Clinic. Nuclear receptors intersect with signaling cascades such as MAPK and PI3K pathways characterized at Weill Cornell Medicine and UCSF through phosphorylation-dependent modulation of receptor activity reported by laboratories at Columbia University.
Nuclear receptors are major drug targets in endocrinology, oncology, and metabolic disease, with therapeutic agents developed by pharmaceutical groups like Pfizer, Roche, GlaxoSmithKline, and academic spinouts from MIT. Selective receptor modulators (SERMs) such as tamoxifen emerged from collaborations involving National Cancer Institute and industry partners, while synthetic agonists and antagonists for PPARs, thyroid receptors, and vitamin D receptor are used clinically following trials at Mayo Clinic and Cleveland Clinic. Mutations and dysregulation in receptors underlie diseases cataloged by World Health Organization and medical genetics programs at The American College of Medical Genetics and Genomics. Ongoing translational research at Howard Hughes Medical Institute, Broad Institute, and industry consortia seeks selective modulators with tissue-specific effects and improved safety profiles.
Category:Transcription factors